This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Osteologix Holdings, PLC
Drug Names(s): strontium malonate
Description: NB S101 is a dual acting bone agent that contains strontium malonate as its active ingredient and is a once-daily oral tablet. In preclinical models of osteoporosis, NB S101 has demonstrated beneficial effects on both reducing bone resorption and increasing high quality strong bone formation and bone mineralization. The effect is believed to be due to a stimulatory effect of strontium on pre-osteoblastic cell differentiation and migration, and a direct or matrix-mediated inhibition of osteoclast activity by strontium.
Osteologix and Servier
In August 2010, Osteologix and the Servier Research Group announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S.
Under the terms of the agreement, Osteologix will receive up to 12 million in upfront and milestone payments. Additionally, Osteologix is eligible to receive up to 30 million in minimum royalty payments creditable against mid to low single digit royalties on sales. Osteologix will also be eligible to receive milestone payments and royalties on product development and sales in Japan. Servier will be responsible for all costs outside of the U.S. associated with development, regulatory approval and commercialization of NB S101. Osteologix will continue to own intellectual property rights for development in the U.S.
In March 2014, Les...See full deal structure in Biomedtracker
NB S101 News
Additional information available to subscribers only: